ABSTRACT

Introduction: Areca nut chewing has been shown to increase the risk of cardiovascular disease, but its association with erectile dysfunction (ED) has not been investigated.

Aim: To investigate the association between areca nut chewing and risk of ED.

Methods: Consecutive men at public health centers for oral malignancy screening or health checkup were invited to complete a questionnaire.

Main Outcome Measure: The Sexual Health Inventory for Men (SHIM).

Results: Of the 2,652 respondents, 1,038 (mean age \( \bar{X} = 43.8 \pm 11.1 \) years) were eligible for the areca nut chewing group and 1,090 non-areca nut chewers were selected as the age-matched control group. In the areca nut group, the mean duration of chewing was 13.2 \( \pm \) 9.6 years, 61.7% consumed more than 10 portions per day, and 76.2% used it with betel leaf, 16.7% used it with betel inflorescence, and 7.1% used it with betel leaf and inflorescence. Smoking, alcohol drinking, obesity, hypertension, and diabetes were more predominant in areca nut chewers compared with controls. ED defined by self-report and by SHIM score was more prevalent in areca nut chewers than in controls (13.7% vs 9.8% and 48.7% vs 43.3%, respectively; \( P < .05 \) for the two comparisons). Areca nut use with betel inflorescence was associated with a higher risk of ED (odds ratio \( \overline{R} = 2.25, \) 95% confidence interval \( T = 1.55 \rightarrow 3.28 \)) with a dose-dependent effect, whereas using it with betel leaf was not (odds ratio \( \overline{R} = 1.00, \) 95% confidence interval \( T = 0.79 \rightarrow 1.26 \)) after adjustment of possible confounders.

Conclusion: Areca nut chewing with betel inflorescence was associated with an increased risk of ED. These findings warrant further studies.

Huang Y-J, Jiann B-P. Association of Areca Nut Chewing With Risk of Erectile Dysfunction. Sex Med 2017;5:e163–e168.

Copyright © 2017, The Authors. Published by Elsevier Inc. on behalf of the International Society for Sexual Medicine. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Key Words: Areca Nut; Betel Inflorescence; Erectile Dysfunction; Psychoactive Substance

INTRODUCTION

Areca nut is the fourth most commonly used psychoactive substance worldwide, after tobacco, alcohol, and caffeine, and its use is addictive.1 The prevalence of areca nut chewing has been estimated to be 10% to 20% of the world’s population.2 The annual national survey in Taiwan showed that approximately 17% of men and 1% of women were areca nut chewers from 2005 through 2015.3

There are two popular ways of preparing areca nut for chewing in Taiwan. One is wrapping a split unripe areca nut with slaked lime paste in a betel leaf; the other is inserting a piece of betel in inflorescence with red lime paste (slaked lime and some local flavoring) into an unripe areca nut. The most important chemical constituents in areca nut are areca alkaloids, including arecoline, arecaidine, guvacine, guacoline, among others.4 Nitrosation of areca alkaloids after ingestion takes place in the mouth especially in the presence of bacteria owing to poor oral hygiene and in the acid condition of the stomach.1 The areca-nut specific nitrosamines have toxic and mutagenic effects on DNA.4 The International Agency for Research on Cancer4 concluded that areca nut is carcinogenic to humans.

Areca nut was considered an aphrodisiac in ancient times. Feeding animals with areca nut was purported to enhance libido and potency.5 The risk factors for erectile dysfunction (ED), a prevalent problem in men, such as obesity,6 metabolic syndrome, diabetes, hypertension, and cardiovascular diseases,2 are more
prevalent in areca nut chewers than in non-chewers. Whether the areca nut affects the chewers' erectile function has not been investigated. A cross-sectional study was conducted to compare the prevalence of ED between areca nut chewers and non-chewers.

OBJECTIVE

The aim of this research was to investigate the association between areca nut chewing and risk of ED.

METHODS

Participants

Each district in Taiwan has a public health center to promote public health. Consecutive men who were undergoing screening for oral malignancy with a history of areca nut chewing or for a health checkup were invited to participate in the study in four of these centers in south Taiwan from 2010 to 2011. The responsible nurses explained the purpose and methods of the study. Participants who consented to join the study were invited to complete a self-administered questionnaire anonymously without any compensation and an informed consent was not required. The protocol of this study was reviewed and approved by the institutional review board at our institution.

Outcome Measures

The questionnaire consisted of nine items, including age, marital status, a checklist of common comorbidities, smoking and alcohol drinking habits, history of areca nut chewing, mean frequency of sexual activity in the past 3 months, a global assessment question (GAQ) for ED, and the five-item Sexual Health Inventory for Men (SHIM). Body height (centimeters) and weight (kilograms) were measured by the nurses. Body mass index (BMI) was calculated as body weight (kilograms) divided by the square of body height (meters), and a BMI higher than 27 kg/m² was categorized as obesity according to the criteria provided by the Department of Health in Taiwan. The presence of smoking was defined as current smoking. The presence of alcohol drinking was defined as alcohol drinking every day or often. The existence of hypertension and diabetes was determined by self-report.

History of areca nut chewing was assessed by three questions. Question 1 was “Do you have a habit of areca nut chewing?” with choices of (i) yes, I have chewed it usually, for xx years; (ii) yes, I have chewed it occasionally for xx years; (iii) yes, I had chewed it for xx years but I quit it; and (iv) no, I have never chewed it before. Question 2 was “What was your average daily consumption of areca nut?” with choices of (i) no more than 10, (ii) 11 to 20, (iii) 21 to 50, (iv) 51 to 100, and (v) more than 100 portions per day. Question 3 was “What was (were) your usual preparation(s) of areca nut?” with choices of (i) with betel leaf and (ii) with betel inflorescence. A subject who chose answer i, ii, or iii for question 1 were defined as an areca nut chewer. The cumulative exposure to areca nut was estimated as the square root of (median daily consumption multiplied by years of chewing duration).

The presence of self-reported ED was defined as the participant responding yes to the GAQ, “Do you consider yourself to have ED?” Erectile function also was assessed by the SHIM. Participants who had a total SHIM score lower than 22 were categorized as having ED. To avoid misclassification as having ED only because of no sexual attempt, subjects who had a zero score for any item of the SHIM were excluded from the analysis.

Statistical Analysis

The χ² test was used for comparison of categorical variables. Normality was assessed for continuous variables. The unpaired Student t-test or Mann-Whitney U-test was used to compare two continuous variables, depending on the normality of distribution. A receiver operating characteristic curve was obtained to estimate the best cutoff of cumulative exposure to areca nut chewing to predict the risk of ED. Multivariate logistic regressions were used to estimate the odds ratio (OR) of comorbidities (obesity, hypertension, diabetes, and ED) for chewing areca nut with adjustment of potential confounders (age, BMI, smoking, alcohol drinking, hypertension, or diabetes) as appropriate. Because there were a few incomplete responses, sample sizes of some calculations were decreased but were never less than 75% of the complete samples.

Data entry was performed using Excel 2003 (Microsoft, Redmond, WA, USA). Statistical analyses were executed using SPSS 17.0 (SPSS, Inc, Chicago, IL, USA). The null hypothesis was rejected for a P value lower than .05.

RESULTS

Of the 2,652 respondents, 43.4% (n = 1,152) reported a habit of areca nut chewing and 56.6% (n = 1,500) denied having such a habit. A total of 1,038 subjects were eligible for the areca nut group after excluding subjects who had no data on age or were younger than 20 years (n = 12), had incomplete SHIM data (n = 50), or had a zero score for the SHIM items (n = 52). An age-matched control group (n = 1,090) was selected from the 1,500 non-areca nut chewers.

The characteristics of the areca nut group and the control group are listed in Table 1. Their mean age was approximately 44 years (range = 20–86 years). The areca nut group was more likely to be divorced than the control group (7.7% vs 3.7%), whereas the two groups had a similar frequency of sexual activity in the past 3 months. Prevalences of smoking (66.8% vs 27.1%), alcohol drinking (35.3% vs 7.4%), and obesity (24.6% vs 18.4%) were greater in the areca nut group than in the control group, as were those of hypertension (22.5% vs 16.0%) and diabetes (8.8% vs 4.8%). The areca nut group had a higher prevalence of ED defined by the response to the GAQ (13.7% vs 9.8%, P = .006) or by SHIM scores (48.7% vs 43.3%, P = .013) than did the control group (Table 1).

Sex Med 2017;5:e163–e168
Table 1. Characteristics of participants

| Variables                                | Control group (n = 1,090) | Areca nut group (n = 1,038) | P value† |
|------------------------------------------|---------------------------|-----------------------------|----------|
| Age (y)                                   | 44.0 ± 11.4 (20–86)       | 43.8 ± 11.1 (20–78)         | .705     |
| Body mass index (kg/m²)                  | 24.3 ± 3.0 (16.1–37.5)    | 25.0 ± 3.5 (16.1–51.9)      | <.001    |
| Obesity                                  | 18.4% (201)               | 24.6% (251)                 | <.001    |
| Marital status                           |                           |                             |          |
| Married                                  | 84.3% (869)               | 80.8% (790)                 | .001     |
| Divorced                                 | 3.7% (38)                 | 7.7% (75)                   |          |
| Single                                   | 12.0% (124)               | 11.6% (113)                 |          |
| Mean sexual frequency in past 3 mo       |                           |                             |          |
| No sexual activity                       | 3.3% (36)                 | 3.2% (33)                   | .229     |
| >2 times/wk                              | 18.9% (204)               | 22.1% (225)                 |          |
| 1–2 times/wk                             | 28.7% (309)               | 25.5% (259)                 |          |
| 1–4 times/mo                             | 32.7% (352)               | 31.2% (317)                 |          |
| <1 time/mo                               | 16.4% (177)               | 17.9% (182)                 |          |
| Current smoker                           | 27.1% (295)               | 66.8% (689)                 | <.001    |
| Daily or frequent alcohol drinking       | 7.4% (81)                 | 35.3% (364)                 | <.001    |
| Hypertension                             | 16.0% (173)               | 22.5% (229)                 | <.001    |
| Diabetes                                 | 4.8% (52)                 | 8.8% (90)                   | <.001    |
| ED classified by SHIM score              | 43.3% (472)               | 48.7% (505)                 | .013     |
| Self-reported ED                         | 9.8% (104)                | 13.7% (140)                 | .006     |

ED = erectile dysfunction; SHIM = Sexual Health Inventory for Men.
*Data are presented as mean ± SD (range) or percentage (number). Obesity was defined as a body mass index higher than 27 kg/m². Diabetes and hypertension were based on self-report. Self-reported ED was defined by a global assessment question.
†The χ² test was used for categorical variables; unpaired Student t-test or Mann-Whitney U-test was used for continuous variables depending on the normality of distribution.

Of the areca nut group, 81.7% were current users and 18.3% were former users and the mean duration of their areca nut use was 13.2 ± 9.6 years (range = 0.5–50; median = 10, interquartile range = 5–20). For the amount of daily consumption, 38.3% chewed fewer than 10 portions, 32.4% chewed 11 to 20 portions, 21.3% chewed 21 to 50 portions, and 8.0% chewed more than 50 portions. For preparation types, 76.2% (n = 728) used areca nuts with betel leaf, 16.7% (n = 160) used areca nuts with betel inflorescence, and 7.1% (n = 68) used areca nuts with betel leaf and inflorescence (Table 2).

Subjects consuming areca nuts with betel leaf and inflorescence (n = 68) were excluded from the following analysis to delineate the consequences of the different preparations. The prevalence rates of ED, based on SHIM score, were 44.8% in betel leaf users (n = 728), 62.5% in betel inflorescence users (n = 160), and 43.3% in controls (P < .001). Betel inflorescence consumers had increased risks for hypertension (OR = 1.74, 95% confidence interval [CI] = 1.09–2.76), diabetes (OR = 2.68, 95% CI = 1.47–4.88), and ED (OR = 2.25, 95% CI = 1.55–3.28), whereas betel leaf consumers had increased risks for obesity (OR = 1.37, 95% CI = 1.06–1.78) and diabetes (OR = 1.64, 95% CI = 1.05–2.56) but no increased risk of ED (OR = 1.00, 95% CI = 0.79–1.26) compared with the controls after adjustment of potential confounders (Table 3). The prevalences of smoking and alcohol drinking were 54.1% vs 70.8% (P < .001) and 30.0% vs 37.9% (P = .06) in the betel inflorescence chewers vs betel leaf chewers, respectively.

Of betel inflorescence consumers, the current and previous chewers had no significant difference in their ED prevalence, which did not change after adjusting potential confounders. A cutoff value of 6.516 for cumulative exposure to areca nut was

Table 2. History of areca nut use in the areca nut group

| Variables                                | Results (n = 1,038) |
|------------------------------------------|---------------------|
| Duration of areca nut use (y)            |                     |
| Mean ± SD (range)                        | 13.2 ± 9.6 (0.5–50) |
| Median (interquartile range)             | 10 (5–20)           |
| History of areca nut use, % (n)          |                     |
| Current user                             | 81.7 (848)          |
| Former user                              | 18.3 (190)          |
| Daily consumption of areca nut (portions), % (n) | 38.3 (364)          |
| <10                                      |                     |
| 11–20                                    | 32.4 (308)          |
| 21–50                                    | 21.3 (202)          |
| 51–100                                   | 5.6 (53)            |
| >100                                     | 2.4 (23)            |
| Type of preparation, % (n)               |                     |
| With betel leaf*                         | 76.2 (728)          |
| With betel inflorescence†                | 16.7 (160)          |
| Both                                     | 7.1 (68)            |

*Wrapping a split unripe areca nut with slaked lime paste in a betel leaf.
†Inserting a piece of betel inflorescence with red lime paste into an unripe areca nut.
Erectile dysfunction was defined as a Sexual Health Inventory for Men score lower than 22; diabetes and hypertension were based on self-report; obesity was defined as a body mass index higher than 27 kg/m². Data are presented as odds ratio (95% confidence interval).

†Wrapping a split unripe areca nut with slaked lime paste in a betel leaf.
††Inserting a piece of betel inflorescence with red lime paste into an unripe areca nut.
*Controlled for age, body mass index, alcohol drinking, diabetes, and hypertension.
‡Controlled for age, alcohol drinking, and smoking.
§Controlled for age, body mass index, alcohol drinking, and smoking.

\[ P < .05; ** P < .01; †† P < .001. \]

Table 3. Odds ratios of comorbidities for using areca nut with different preparations

| Variables | With betel leaf (n = 728) | With betel inflorescence (n = 160) | Control (n = 1,090) |
|-----------|---------------------------|-----------------------------------|---------------------|
| Erectile dysfunction | 1.00 (0.79–1.26) | 2.25 (1.55–3.28)†† | Reference |
| Obesity | 1.37 (1.06–1.78)§ | 1.21 (0.80–1.84) | Reference |
| Hypertension | 1.32 (0.97–1.79) | 1.74 (1.09–2.76)* | Reference |
| Diabetes | 1.64 (1.05–2.56)§ | 2.68 (1.47–4.88)** | Reference |

DISCUSSION

This study found that areca nut users had more problems with obesity, hypertension, diabetes, and ED than the non-chewers. Chewing areca nut with betel inflorescence increased the risk of ED in a dose-response relation after adjustment of possible confounders, whereas chewing it with betel leaf did not.

Link of Areca Nut Chewing to Obesity, Hypertension, and Diabetes

A meta-analysis of observational studies demonstrated that areca nut chewers had an adjusted relative risk of 1.47 for obesity and for diabetes (P < .001 for the two comparisons) and of 1.45 for hypertension (P = .06) compared with non-chewers. These figures were comparable with ours (Table 3). Unhealthy lifestyles could be responsible in part for the link between them. Areca nut chewers were prone to have smoking and alcohol drinking habits in the present study. Other studies reported areca nut chewers had less physical activity and consumed a more unhealthy diet than non-chewers did. The ingredients of areca nut and its additives also contribute to the increased risk of obesity, hypertension, and diabetes.4,10,12–23

Diabetes

The nitrosated derivatives of areca alkaloids damage DNA and generate reactive oxygen species.4 This oxidative stress and DNA damage activate proinflammatory factors and promote insulin resistance.12,13 Moreover, areca alkaloids inhibit the uptake of γ-aminobutyric acid (GABA)14 and are strong blockers of the GABA receptor.15 Because GABA suppresses the secretion of glucagon,16 areca nut chewing can result in excessive secretion of glucagon, leading to hyperglycemia.

Hypertension

Areca nut and betel inflorescence can exert sympathomimetic effects.7,18 The oxidative stress caused by nitrosated areca alkaloids could lead to increased risk of hypertension.19 However, areca II-5-C, a fraction isolated from areca nut, exhibits potent angiotensin-converting enzyme inhibitory activity in vitro and produces a lasting dose-related antihypertensive effect in rats.20

Obesity

GABA can stimulate appetite.21 The inhibitory effect of areca alkaloids on GABA15 can suppress appetite. A decreased increment of BMI was observed after areca nut use in a cohort study.22 In contrast, a cross-sectional study observed that areca nut chewers were likely to have general and central obesity, which did not change after adjustment of confounders including physical activity.10 This could be attributed to the insulin resistance in areca nut chewers given that hyperinsulinemia contributes to obesity.23

Link of Areca Nut Chewing to ED

Because areca nut chewing increases the risks of diabetes, hypertension, and obesity, areca nut chewers were expected to be more likely to have ED. Our results showed that chewing areca nut only with betel inflorescence was associated with an increased risk of ED, which suggested that factors other than areca nut were responsible for the increased risk.

Betel leaf and inflorescence come from a tropical plant named *Piper betel* Linn. Betel leaf was found to have some beneficial effects, such as antioxidant, anticancer, and anti-inflammatory, in vitro and in animal studies.24 Betel inflorescence contains eugenol (6.2%) and safrole (78.9%).4 Safrole is a possible human carcinogen.25 Unlike the more popular preparation of areca nut with betel leaf, consumption of areca nut with betel inflorescence is common only in Taiwan and Melanesia.4 Probably owing to...
the public awareness of its carcinogenicity, the use of betel inflorescence has greatly decreased in recent years.26

Among the various preparations of areca nut, using betel inflorescence has the highest cancer risk.27 No clinical research has compared the impact of different preparations of areca nut on metabolic disorders or cardiovascular diseases. The current results showed that the risks of diabetes and hypertension were greater in betel inflorescence users than in betel leaf users. Some other causes might be responsible for the increased ED risk in betel inflorescence users because it remained significant after adjusting for diabetes and hypertension. A plausible conjecture was that betel inflorescence chewers had more negative lifestyles than betel leaf users. This hypothesis seemed unlikely because the prevalences of smoking and alcohol drinking were not higher in the betel inflorescence chewers than betel leaf chewers. Another hypothesis was that the ED-associated stress and depression prompted men to chew betel inflorescence. A long duration of areca nut use (median = 10 years) implied the users began to use it at a young age before they developed ED. There was no reason to believe that men with ED were more likely to choose betel inflorescence to relieve the stress than to choose betel leaf.

The oxidative stress caused by safrole in betel inflorescence28 can compromise penile vascular function and penile erection. Safrole can be used to produce 3,4-methylenedioxy-methamphetamine,29 which was reported to impede erection and orgasm.30 The spices contained in the red lime used with betel inflorescence28 have the highest cancer risk.27 No clinical research was conducted to compare the risks of areca nut chewing with betel inflorescence but not in those chewing it with betel leaf. The association of ED and chewing areca nut with betel inflorescence exhibited a dose-response effect, independent of obesity, hypertension, and diabetes. The effect of areca nut on users’ erectile function was neutral. The increased diabetes, hypertension, and obesity and the additives with betel inflorescence and red lime contributed to an increased ED risk in subjects chewing areca nut with betel inflorescence. More research is needed to verify the association between areca nut chewing and sexual function.

**Corresponding Author:** Bang-Ping Jiann, MD, Department of Surgery, Kaohsiung Veterans General Hospital, Kaohsiung and School of Medicine, National Yang-Ming University, No 386, Dajhong First Road, Zuoying District, Kaohsiung City 81362, Taiwan. Tel: 886-7-3422121, ext 8360; Fax: 886-7-3415037; E-mail: bpjjian@vghks.gov.tw or bpjiann@gmail.com

**Conflicts of Interest:** The authors report no conflicts of interest.

**Funding:** None.

**STATEMENT OF AUTHORSHIP**

**Category 1**

(a) **Conception and Design**
Yung-Jui Huang; Bang-Ping Jiann

(b) **Acquisition of Data**
Yung-Jui Huang; Bang-Ping Jiann

(c) **Analysis and Interpretation of Data**
Yung-Jui Huang; Bang-Ping Jiann

**Category 2**

(a) **Drafting the Article**
Yung-Jui Huang; Bang-Ping Jiann

(b) **Revising It for Intellectual Content**
Yung-Jui Huang; Bang-Ping Jiann

**Category 3**

(a) **Final Approval of the Completed Article**
Yung-Jui Huang; Bang-Ping Jiann

**REFERENCES**

1. Winstock A. Areca nut-abuse liability, dependence and public health. Addict Biol 2002;7:133-138.
2. Gupta PC, Warnakulasuriya S. Global epidemiology of areca nut usage. Addict Biol 2002;7:77-83.
3. Health Promotion Administration, Ministry of Health and Welfare, Executive Yuen, Republic of China. Health Statistics, 2005—2015. Taipei: Department of Health, Executive Yuen, Republic of China; 2015. Available at: http://www.hpa.gov.tw/Bhpnet/Web/HealthTopic/TopicBulletin.aspx?No=20110310003&parentid=201109140001. Accessed July 26, 2017.

4. International Agency for Research on Cancer. Betel-quid and areca-nut chewing and some areca-nut-derived nitrosamines. IARC Monogr Eval Carcinog Risks Hum 2004;85:1-334.

5. Anthikat RRN, Micheal A, Ignacimuthu S. Aphrodisiac effect of Areca catechu L. and Pedalium murex in rats. J Mens Health 2013;10:65-70.

6. Esposito K, Giugliano D. Obesity, the metabolic syndrome, and sexual dysfunction in men. Clin Pharmacol Ther 2011; 90:169-173.

7. Feldman HA, Goldstein I, Hatzichristou DG, et al. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Ageing Study. J Urol 1994;151:54-61.

8. Yamada T, Hara K, Kadowaki T. Chewing betel quid and the risk of metabolic disease, cardiovascular disease, and all-cause mortality: a meta-analysis. PLoS One 2013;8:e70679.

9. Jiann BP. Using the International Index of Erectile Function—5 to assess erectile function in epidemiological studies. J Sex Med 2012;9:327.

10. Lin WY, Pi-Sunyer X, Liu CS, et al. Betel nut chewing is strongly associated with general and central obesity in Chinese male middle-aged adults. Obesity 2009;17:1247-1254.

11. Guo SE, Huang TJ, Huang JC, et al. Alcohol, betel-nut and cigarette consumption are negatively associated with health promoting behaviors in Taiwan: a cross-sectional study. BMC Public Health 2013;13:257.

12. Reuter S, Gupta SC, Chaturvedi MM, et al. Oxidative stress, inflammation, and cancer: how are they linked? Free Radic Biol Med 2010;49:1603-1616.

13. Henriksen EJ, Diamond-Stanic MK, Marchionne EM. Oxidative stress and the etiology of insulin resistance and type 2 diabetes. Free Radic Biol Med 2011;51:993-999.

14. Lodge D, Johnston GA, Curtis DR, et al. Effects of the areca nut constituents arecaidine and guvacine on the action of GABA in the cat central nervous system. Brain Res 1977; 136:513-522.

15. Schousboe A, Thorbek P, Hertz L, et al. Effects of GABA analogues of restricted conformation on GABA transport in astrocytes and brain cortex slices and on GABA receptor binding. J Neurochem 1979;33:181-189.

16. Xu E, Kumar M, Zhang Y, et al. Intra-islet insulin suppresses glucagon release via GABA-GABA A receptor system. Cell Metab 2006;3:47-58.

17. Chu NS. Neurological aspects of areca and betel chewing. Addict Biol 2002;7:111-114.

18. Chen SJ, Wu BN, Yeh JL, et al. C-fiber-evoked autonomic cardiovascular effects after injection of Piper betel inflorescence extracts. J Ethnopharmacol 1995;45:183-188.

19. Dhalla NS, Temsah RM, Netticadan T. Role of oxidative stress in cardiovascular diseases. J Hypertens 2000;18:655-673.

20. Inokuchi J, Okabe H, Yamauchi T, et al. Antihypertensive substance in seeds of Areca catechu L. Life Sci 1986; 38:1375-1382.

21. Delgado TC. Glutamate and GABA in appetite regulation. Front Endocrinol 2013;4:103.

22. Strickland SS, Duffield AE. Anthropometric status and resting metabolic rate in users of the areca nut and smokers of tobacco in rural Sarawak. Ann Hum Biol 1997;24:453-474.

23. Kahn BB, Flier JS. Obesity and insulin resistance. J Clin Invest 2000;106:473-481.

24. Toprani R, Patel D. Betel leaf: revisiting the benefits of an ancient Indian herb. South Asian J Cancer 2013;2:140-141.

25. Ames BN, Magaw R, Gold LS. Ranking possible carcinogenic hazards. Science 1987;236:271-276.

26. Lee CH, Ko AM, Warnakulasuriya S, et al. Intercountry prevalences and practices of betel-quid use in south, southeast and eastern Asia regions and associated oral preneoplastic disorders: an international collaborative study by Asian betel-quid consortium of south and east Asia. Int J Cancer 2011;129:1741-1751.

27. International Agency for Research on Cancer. Personal habits and indoor combustions. IARC Monogr Eval Carcinog Risks Hum 2012;100E:333-372.

28. Liu TY, Chen CC, Chen CL, et al. Safrole-induced oxidative damage in the liver of Sprague-Dawley rats. Food Chem Toxicol 1999;37:697-702.

29. Rätsch C. The encyclopedia of psychoactive plants: ethnopharmacology and its applications. Rochester, VT: Park Street Press; 2005. p. 107-115.

30. Peugh J, Belenko S. Alcohol, drugs and sexual function: a review. J Psychoactive Drugs 2001;33:223-232.